-
While bones can regrow themselves when they break, teeth aren’t so lucky, and that leads to millions of people worldwide suffering from some form of edentulism, a.k.a. toothlessness.
-
Now, Japanese researchers are moving a promising, tooth-regrowing medicine into human trials—the first patients will be receiving the drug intravenously in September of this year.
-
If the trial is successful, the researchers hope the drug will become available for all forms of toothlessness sometime around 2030.
The average adult human body contains 206 bones—the hardened mixtures of calcium, minerals, and collagen that provide the biological scaffolding that walks us through our day. While we may not think of them much, bones are incredibly resilient. But if they do break, they have this nifty trick of regrowing themselves.
Teeth, however, are not bones. Although they’re made of some of the same stuff and are the hardest material in the human body (thanks to its protective layer of enamel), they lack the crucial ability to heal and regrow themselves. But that may not always be the case. Japanese researchers are moving forward with an experimental drug that promises to regrow human teeth, and human trials are set to begin in September.
“We want to do something to help those who are suffering from tooth loss or absence,” Katsu Takahashi, the head of dentistry at the medical research institute at Kitano Hospital in Osaka, told The Mainichi. “While there has been no treatment to date providing a permanent cure, we feel that people’s expectations for tooth growth are high.”
This development follows years of study around a particularly antibody named Uterine sensitization–associated gene-1 (USAG-1), which has been shown to inhibit the growth of teeth in ferrets and mice. Back in 2021, scientists from the Kyoto University—who will also be involved in future human trials—discovered a monoclonal antibody (a technique usually used in fighting cancer) that disrupted the interaction between USAG-1 and molecules known as bone morphogenetic protein, or BMP.
“We knew that suppressing USAG-1 benefits tooth growth. What we did not know was whether it would be enough,” Kyoto University’s Katsu Takahashi, a co-author of the study, said in a press statement at the time. “Ferrets are diphyodont animals with similar dental patterns to humans.”
Now, scientists will see just how similar, because humans will soon undergo a similar trial in September of this year. Lasting 11 months, this study will focus on 30 males between the ages of 30 and 64—each missing at least one tooth. The drug will be administered intravenously to prove its effectiveness and safety, and luckily, no side effects have been reported in previous animal studies.
If all goes well, Kitano Hospital will administer the treatment to patients between the ages of 2 to 7 who are missing at least four teeth, with the end goal of having a tooth-regrowing medicine available by the year 2030. While these treatments are currently focused on patients with congenital tooth deficiency, Takahashi hopes the treatment will be available for anyone who’s lost a tooth.
You Might Also Like
Source Agencies
